JP2019511528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511528A5 JP2019511528A5 JP2018553365A JP2018553365A JP2019511528A5 JP 2019511528 A5 JP2019511528 A5 JP 2019511528A5 JP 2018553365 A JP2018553365 A JP 2018553365A JP 2018553365 A JP2018553365 A JP 2018553365A JP 2019511528 A5 JP2019511528 A5 JP 2019511528A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- solvate
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 **1C(*)=*C=C1* Chemical compound **1C(*)=*C=C1* 0.000 description 6
- LCNLCZYJDNFGLE-UHFFFAOYSA-N CC[n]1nc(C2CC2)cc1Nc1c(c(c([nH]2)c3)cc(OC)c3-c3c(C)[o]nc3C)c2nc(C(NCCOCCOCCOCCOCCOCCOCCOCCNc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)=O)n1 Chemical compound CC[n]1nc(C2CC2)cc1Nc1c(c(c([nH]2)c3)cc(OC)c3-c3c(C)[o]nc3C)c2nc(C(NCCOCCOCCOCCOCCOCCOCCOCCNc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)=O)n1 LCNLCZYJDNFGLE-UHFFFAOYSA-N 0.000 description 1
- KELXSFPNQGNTTJ-UHFFFAOYSA-N CC[n]1nc(C2CC2)cc1Nc1c(c(c([nH]2)c3)cc(OC)c3-c3c(C)[o]nc3C)c2nc(CNCCCCNc2cccc(C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)n1 Chemical compound CC[n]1nc(C2CC2)cc1Nc1c(c(c([nH]2)c3)cc(OC)c3-c3c(C)[o]nc3C)c2nc(CNCCCCNc2cccc(C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)n1 KELXSFPNQGNTTJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321499P | 2016-04-12 | 2016-04-12 | |
| US62/321,499 | 2016-04-12 | ||
| US201662393888P | 2016-09-13 | 2016-09-13 | |
| US62/393,888 | 2016-09-13 | ||
| PCT/US2017/026278 WO2017180417A1 (en) | 2016-04-12 | 2017-04-06 | Bet protein degraders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511528A JP2019511528A (ja) | 2019-04-25 |
| JP2019511528A5 true JP2019511528A5 (enExample) | 2020-05-14 |
| JP7072519B2 JP7072519B2 (ja) | 2022-05-20 |
Family
ID=58548921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553365A Expired - Fee Related JP7072519B2 (ja) | 2016-04-12 | 2017-04-06 | Ｂｅｔタンパク質分解剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10633386B2 (enExample) |
| EP (1) | EP3442976B1 (enExample) |
| JP (1) | JP7072519B2 (enExample) |
| KR (1) | KR20180132861A (enExample) |
| CN (1) | CN109311890B (enExample) |
| AU (1) | AU2017250076B2 (enExample) |
| BR (1) | BR112018070859A2 (enExample) |
| CA (1) | CA3020541A1 (enExample) |
| IL (1) | IL262139B (enExample) |
| MX (1) | MX384905B (enExample) |
| RU (1) | RU2752677C2 (enExample) |
| SG (1) | SG11201808729WA (enExample) |
| UA (1) | UA123168C2 (enExample) |
| WO (1) | WO2017180417A1 (enExample) |
| ZA (1) | ZA201806969B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3892272B1 (en) | 2016-04-22 | 2024-07-24 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CA3025806C (en) * | 2016-06-23 | 2023-04-04 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use |
| EP3641762B1 (en) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN109422751B (zh) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 |
| CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| EP3679028A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| WO2019094772A1 (en) * | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l degraders and methods of treatment therewith |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| AU2019323446B2 (en) | 2018-08-22 | 2025-01-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| US12459921B2 (en) * | 2018-09-30 | 2025-11-04 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
| EP3863642A4 (en) * | 2018-10-09 | 2022-06-29 | The Regents of the University of California | Covalent targeting of e3 ligases |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| EP3908291A4 (en) * | 2019-01-07 | 2023-01-11 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULAR DEGRADERS OF FKBP12 VIA RECRUITMENT OF THE VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) AND USE IN DTAG SYSTEMS |
| BR112021014220A2 (pt) * | 2019-01-22 | 2022-01-18 | Merck Patent Gmbh | Derivados heterocíclicos |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| WO2020249048A1 (zh) * | 2019-06-12 | 2020-12-17 | 上海科技大学 | Alk蛋白调节剂及其抗肿瘤应用 |
| TW202126638A (zh) * | 2019-09-30 | 2021-07-16 | 日商協和麒麟股份有限公司 | Bet分解劑 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| JP7692924B2 (ja) | 2020-02-26 | 2025-06-16 | クルゲン（シャンハイ），インク． | トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法 |
| IL295709A (en) | 2020-03-05 | 2022-10-01 | C4 Therapeutics Inc | Compounds for targeted degradation of brd9 |
| CN113387932B (zh) * | 2020-03-14 | 2023-05-09 | 成都先导药物开发股份有限公司 | 一种诱导brd4蛋白降解的双功能化合物 |
| CN112920176B (zh) * | 2020-05-25 | 2022-11-04 | 四川大学华西医院 | 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用 |
| EP4192458A4 (en) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | COMPOUNDS FOR TARGETED DEGRADATION OF RET |
| WO2022051616A1 (en) * | 2020-09-03 | 2022-03-10 | Board Of Regents Of The University Of Nebraska | Cdk targeted heterobifunctional small molecule proteolysis targeting chimeras |
| BR112023023065A2 (pt) | 2021-05-05 | 2024-01-30 | Biogen Ma Inc | Compostos para direcionar a degradação da tirosina quinase de bruton |
| CN113336801B (zh) * | 2021-06-08 | 2023-08-22 | 中国人民解放军空军军医大学 | 含有bet抑制剂的四价铂配合物与应用 |
| KR20240035526A (ko) | 2021-07-07 | 2024-03-15 | 바이오젠 엠에이 인코포레이티드 | Irak4 단백질의 분해를 표적하는 화합물 |
| JP2024525580A (ja) | 2021-07-07 | 2024-07-12 | バイオジェン・エムエイ・インコーポレイテッド | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 |
| WO2024006776A1 (en) | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and medical use thereof |
| AU2023298115A1 (en) | 2022-06-27 | 2025-01-16 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and use thereof |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| CN116585322B (zh) * | 2023-01-16 | 2023-10-13 | 中山大学中山眼科中心 | Bet蛋白降解剂在预防和治疗视网膜退行性改变相关疾病中的应用 |
| EP4720059A1 (en) | 2023-05-24 | 2026-04-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025007000A1 (en) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| TW202523291A (zh) | 2023-11-02 | 2025-06-16 | 美商金橘生物科技公司 | 降解劑及其用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57501692A (enExample) | 1980-09-24 | 1982-09-16 | ||
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| DE69717160T2 (de) | 1996-09-13 | 2003-05-08 | Mitsubishi Pharma Corp., Osaka | Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| FR2843126B1 (fr) | 2002-08-01 | 2006-01-27 | Cis Bio Int | "methode de determination d'une activite enzymatique endoglycosidase" |
| WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| DK2118074T3 (en) | 2007-02-01 | 2014-03-10 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| EP2358697B1 (en) * | 2008-10-29 | 2015-10-21 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer. |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| DE102009051823A1 (de) | 2009-11-04 | 2011-05-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Einkristallines Schweißen von direktional verfestigten Werkstoffen |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| SI2496582T1 (sl) | 2009-11-05 | 2016-04-29 | Glaxosmithkline Llc Corporation Service Company | Benzodiazepinski inhibitor bromodomene |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| SG10201501062SA (en) * | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| JP5913292B2 (ja) | 2010-05-14 | 2016-04-27 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 代謝を調節する組成物および方法 |
| MX384074B (es) | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| ES2526671T3 (es) | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| CA2828212A1 (en) | 2011-02-23 | 2012-08-30 | Shiraz Mujtaba | Inhibitors of bromodomains as modulators of gene expression |
| EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| JP2015508414A (ja) * | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| EP2838881B1 (en) | 2012-04-20 | 2018-08-08 | AbbVie Inc. | Isoindolone derivatives |
| WO2013185284A1 (en) | 2012-06-12 | 2013-12-19 | Abbott Laboratories | Pyridinone and pyridazinone derivatives |
| CA2902856C (en) * | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| JP6401773B2 (ja) * | 2013-03-11 | 2018-10-10 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法 |
| JP2017511801A (ja) * | 2014-02-28 | 2017-04-27 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体 |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| CN119591582A (zh) * | 2014-04-14 | 2025-03-11 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
| US10307407B2 (en) * | 2015-02-27 | 2019-06-04 | The Regents Of The University Of Michigan | 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| AU2017246453A1 (en) * | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
-
2017
- 2017-04-06 AU AU2017250076A patent/AU2017250076B2/en not_active Ceased
- 2017-04-06 UA UAA201811059A patent/UA123168C2/uk unknown
- 2017-04-06 CA CA3020541A patent/CA3020541A1/en active Pending
- 2017-04-06 RU RU2018139537A patent/RU2752677C2/ru active
- 2017-04-06 BR BR112018070859A patent/BR112018070859A2/pt not_active IP Right Cessation
- 2017-04-06 CN CN201780036434.9A patent/CN109311890B/zh not_active Expired - Fee Related
- 2017-04-06 EP EP17717993.4A patent/EP3442976B1/en active Active
- 2017-04-06 KR KR1020187032621A patent/KR20180132861A/ko not_active Abandoned
- 2017-04-06 US US16/093,160 patent/US10633386B2/en active Active
- 2017-04-06 JP JP2018553365A patent/JP7072519B2/ja not_active Expired - Fee Related
- 2017-04-06 MX MX2018012379A patent/MX384905B/es unknown
- 2017-04-06 SG SG11201808729WA patent/SG11201808729WA/en unknown
- 2017-04-06 WO PCT/US2017/026278 patent/WO2017180417A1/en not_active Ceased
-
2018
- 2018-10-04 IL IL262139A patent/IL262139B/en active IP Right Grant
- 2018-10-18 ZA ZA2018/06969A patent/ZA201806969B/en unknown